TABLE 1.
Immunohistochemical data of BFHs and BCCs
| Patient number | Histological diagnosis | CD34 | BCL2 | Ber‐EP4 | AR |
|---|---|---|---|---|---|
| 1 | BFH | 3 | 2 (P) | 3 | 1 |
| BCC infundibolo‐cystic | 0 | 3 (P+C) | 3 | 2 | |
| 2 | BCC superficial | 0 | 3 (P+C) | 3 | 3 |
| BCC superficial | 0 | 3 (P+C) | 3 | 1 | |
| BFH | 3 | 2 (P) | 3 | 1 | |
| BFH | 1 | 2 (P) | 3 | 1 | |
| BFH | 3 | 2 (P) | 3 | 3 | |
| BFH | 1 | 2 (P) | 3 | 1 | |
| 3 | BFH | 2 | 2 (P) | 3 | 1 |
| BFH | 2 | 2 (P) | 3 | 1 | |
| BFH | 3 | 1 (P) | 3 | 1 |
Score 0 (no positive cells); 1 (small fraction of positive cells); 2 (moderate fraction of positive cells); 3 (big fraction of positive cells).
Abbreviations: AR, Androgen receptor; BCC, basal cell carcinoma; Bcl2, B‐cell lymphoma 2; Ber‐Ep4, Ep‐CAM/cell adhesion molecule epithelial; BFH, basaloid follicular hamartoma; CD34, Cluster of differentiation 34; P, peripheral; P+C, peripheral and central.